Mechanism of free fatty acid-induced insulin resistance in humans

M Roden, T B Price, G Perseghin, K F Petersen, D L Rothman, G W Cline, G I Shulman, M Roden, T B Price, G Perseghin, K F Petersen, D L Rothman, G W Cline, G I Shulman

Abstract

To examine the mechanism by which lipids cause insulin resistance in humans, skeletal muscle glycogen and glucose-6-phosphate concentrations were measured every 15 min by simultaneous 13C and 31P nuclear magnetic resonance spectroscopy in nine healthy subjects in the presence of low (0.18 +/- 0.02 mM [mean +/- SEM]; control) or high (1.93 +/- 0.04 mM; lipid infusion) plasma free fatty acid levels under euglycemic (approximately 5.2 mM) hyperinsulinemic (approximately 400 pM) clamp conditions for 6 h. During the initial 3.5 h of the clamp the rate of whole-body glucose uptake was not affected by lipid infusion, but it then decreased continuously to be approximately 46% of control values after 6 h (P < 0.00001). Augmented lipid oxidation was accompanied by a approximately 40% reduction of oxidative glucose metabolism starting during the third hour of lipid infusion (P < 0.05). Rates of muscle glycogen synthesis were similar during the first 3 h of lipid and control infusion, but thereafter decreased to approximately 50% of control values (4.0 +/- 1.0 vs. 9.3 +/- 1.6 mumol/[kg.min], P < 0.05). Reduction of muscle glycogen synthesis by elevated plasma free fatty acids was preceded by a fall of muscle glucose-6-phosphate concentrations starting at approximately 1.5 h (195 +/- 25 vs. control: 237 +/- 26 mM; P < 0.01). Therefore in contrast to the originally postulated mechanism in which free fatty acids were thought to inhibit insulin-stimulated glucose uptake in muscle through initial inhibition of pyruvate dehydrogenase these results demonstrate that free fatty acids induce insulin resistance in humans by initial inhibition of glucose transport/phosphorylation which is then followed by an approximately 50% reduction in both the rate of muscle glycogen synthesis and glucose oxidation.

References

    1. J Clin Invest. 1993 Jul;92(1):91-8
    1. Am J Physiol. 1993 Apr;264(4 Pt 1):E599-605
    1. Biochem J. 1964 Dec;93(3):652-65
    1. Ann N Y Acad Sci. 1965 Oct 8;131(1):324-33
    1. Am J Physiol. 1979 Sep;237(3):E214-23
    1. Metabolism. 1982 Nov;31(11):1128-36
    1. J Clin Invest. 1983 Nov;72(5):1737-47
    1. J Clin Invest. 1984 Apr;73(4):1185-90
    1. Metabolism. 1987 May;36(5):502-6
    1. Metabolism. 1988 Apr;37(4):323-9
    1. Diabetes. 1988 Aug;37(8):1020-4
    1. N Engl J Med. 1990 Jan 25;322(4):223-8
    1. Diabetes. 1990 Mar;39(3):383-9
    1. J Clin Invest. 1990 Jun;85(6):1785-92
    1. Am J Physiol. 1991 Apr;260(4 Pt 2):R698-703
    1. J Clin Endocrinol Metab. 1991 Jun;72(6):1268-77
    1. Am J Physiol. 1991 May;260(5 Pt 1):E680-9
    1. J Appl Physiol (1985). 1994 Jan;76(1):104-11
    1. J Clin Invest. 1994 Jun;93(6):2438-46
    1. Diabetologia. 1994 Sep;37 Suppl 2:S155-61
    1. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):983-7
    1. Lancet. 1963 Apr 13;1(7285):785-9
    1. J Clin Invest. 1991 Sep;88(3):960-6
    1. Clin Sci (Lond). 1992 Feb;82(2):219-26
    1. J Clin Invest. 1992 Apr;89(4):1069-75
    1. Magn Reson Med. 1992 Sep;27(1):13-20
    1. Science. 1992 Oct 30;258(5083):766-70
    1. Endocrinology. 1993 Jan;132(1):13-22
    1. Magn Reson Med. 1993 Sep;30(3):347-50

Source: PubMed

3
Subscribe